Literature DB >> 10679515

Glucocorticoid-remediable aldosteronism and pregnancy.

J A Wyckoff1, E W Seely, S Hurwitz, B F Anderson, R P Lifton, R G Dluhy.   

Abstract

Glucocorticoid-remediable aldosteronism (GRA) is a hereditary form of primary hyperaldosteronism that presents with hypokalemia and hypertension from childhood onward. GRA is characterized by the ectopic production of aldosterone in the cortisol-producing zona fasciculata under the regulation of adrenocorticotrophic hormone. Despite the early age of onset, no previous reports of pregnancy and GRA exist. Therefore, we set out to describe the maternal and fetal outcomes of pregnancy in women with GRA. Data regarding the blood pressure and pregnancy outcomes were collected in a retrospective chart review of prenatal and hospital records of 35 pregnancies in 16 women with genetically proven GRA. A total of 6% of pregnancies in women with GRA (GRA+) were complicated by preeclampsia. The published rates of preeclampsia in general obstetric populations vary from 2.5% to 10%. Despite the lack of an apparent increase in the rate of preeclampsia, GRA+ women with chronic hypertension had a high rate (39%) of pregnancy-aggravated hypertension. Starting with a higher baseline blood pressure, maternal blood pressure plotted over the time course of pregnancy followed a quadratic curve similar to that previously described in normal pregnancy. Mean gestational age at delivery was 39.1 weeks. Mean birth weight, excluding the 3 sets of twins, was 3219 g. However, infants of GRA+ mothers with pregnancy-aggravated hypertension tended to have lower birth weights than those that did not (3019 g versus 3385 g, respectively; P=0.08). The primary cesarean section rate was 32%, which is approximately double that seen in other general or hypertensive obstetric populations. In summary, GRA+ women did not seem to have an increased risk of preeclampsia. However, GRA+ women with chronic hypertension seem to be at an increased risk for an exacerbation of their hypertension during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679515     DOI: 10.1161/01.hyp.35.2.668

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

Review 1.  Secondary Hypertension in Pregnancy.

Authors:  Line Malha; Phyllis August
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 2.  Regulation of transport in the connecting tubule and cortical collecting duct.

Authors:  Alexander Staruschenko
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

3.  Pregnancy normalized familial hyperaldosteronism type I: a novel role for progesterone?

Authors:  C Campino; P Trejo; C A Carvajal; A Vecchiola; C Valdivia; C A Fuentes; J F Delgado; C F Lagos; M Aglony; C Carrasco; A Martinez-Aguayo; H García; C Loureiro; C E Fardella
Journal:  J Hum Hypertens       Date:  2014-06-19       Impact factor: 3.012

Review 4.  Genetics of arterial hypertension and hypotension.

Authors:  Dieter Rosskopf; Markus Schürks; Christian Rimmbach; Rafael Schäfers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-30       Impact factor: 3.000

Review 5.  Primary aldosteronism in pregnancy.

Authors:  Vittorio Forestiero; Elisa Sconfienza; Paolo Mulatero; Silvia Monticone
Journal:  Rev Endocr Metab Disord       Date:  2022-05-10       Impact factor: 9.306

Review 6.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 7.  Adrenal disorders in pregnancy.

Authors:  Silvia Monticone; Richard J Auchus; William E Rainey
Journal:  Nat Rev Endocrinol       Date:  2012-09-11       Impact factor: 43.330

Review 8.  Endocrine causes of hypertension in pregnancy.

Authors:  Alison H Affinati; Richard J Auchus
Journal:  Gland Surg       Date:  2020-02

9.  Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Authors:  Chung-Yi Cheng; Hung-Wei Liao; Kang-Yung Peng; Tso-Hsiao Chen; Yen-Hung Lin; Jeff S Chueh; Vin-Cent Wu
Journal:  Biomedicines       Date:  2021-12-02

Review 10.  A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.

Authors:  Viola Sanga; Teresa Maria Seccia; Gian Paolo Rossi
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.